Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nasal Glucagon vs SC Glucagon for Hypoglycemia in T1D
NCT01556594Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2012
- Primary completion
- Jul 2012
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of glucagon in hypoglycemia (4 arms), sponsored by Eli Lilly and Company. Primary endpoints: Percentage of Responders at 30 minutes and Number of Participants With at Least One Adverse Event at 3 hours. Started Mar 2012; status: completed.
02
Drugs
glucagon
03
Conditions
hypoglycemia
Beyond the preview
Go deeper on NCT01556594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01556594.